Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of two abstracts on its drug neratinib that will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress, which will be held September 8 12 in Madrid, Spain. Abstracts are available to the public online on the ESMO website: http://www.esmo.org.
Abstract #1490: Neratinib after trastuzumab-based adjuvant therapy in early stage HER2-positive breast cancer:5-year analysis of the Phase III ExteNET trial.The abstract will be presented as a proffered paper oral session on Friday, September 8.
Abstract #177P:Effects of neratinib on health-related quality of life in early stage HER2-positive breast cancer.The abstract will be displayed as a poster on Monday, September 11.
The ExteNET trial is a double-blind, placebo-controlled, Phase III trial of neratinib versus placebo after adjuvant treatment with trastuzumab (Herceptin) in women with early stage HER2-positive breast cancer.
U.S. Approval of Neratinib (NERLYNX)
Neratinib was approved by the U.S. Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets.
About HER2-Positive Breast Cancer
Approximately 20% to 25% of breast cancer tumors over-express the HER2 protein. HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death. Although research has shown that trastuzumab can reduce the risk of early stage HER2-positive breast cancer returning after surgery, up to 25% of patients treated with trastuzumab experience recurrence.
Indication
NERLYNX is a tyrosine kinase inhibitor indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy.
To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance.More information on the Puma Patient Lynx program can be found at http://www.NERLYNX.com or 1-855-816-5421.
The full prescribing information for NERLYNX is available at http://www.NERLYNX.com. The recommended dose of NERLYNX is 240 mg (six 40 mg tablets) given orally once daily with food, continuously for one year. Antidiarrheal prophylaxis should be initiated with the first dose of NERLYNX and continued during the first 2 months (56 days) of treatment and as needed thereafter.
Important Safety Information
There are possible side effects of NERLYNX. Patients must contact their doctor right away if they experience any of these symptoms. NERLYNX treatment may be stopped or the dose may be lowered if the patient experiences any of these side effects.
Diarrhea
Diarrheais a common side effect ofNERLYNX. The diarrhea may be severe, and you may get dehydrated. Your healthcare provider should prescribe the medicine loperamide for you during your first 2 cycles (56 days) of NERLYNX and then as needed. To help prevent or reduce diarrhea:
Contact your healthcare provider right away if you have severe diarrhea or if you have diarrhea along with weakness, dizziness or fever.
Liver Problems
Changes in liver function tests are common with NERLYNX. The patients doctor will do tests before starting treatment, monthly during the first 3 months, and then every 3 months as needed during treatment with NERLYNX. NERLYNX treatment may be stopped or the dose may be lowered if your liver tests show severe problems. Symptoms of liver problems may include tiredness, nausea, vomiting, pain in the right upper stomach area (abdomen), fever, rash, itching or yellowing of your skin or whites of your eyes.
Pregnancy
Patients should tell their doctor if they are planning to become pregnant, are pregnant, plan to breastfeed, or are breastfeeding. NERLYNX can harm your unborn baby. Birth control should be used while a patient is receiving NERLYNX and for at least 1 month after the last dose. If patients are exposed to NERLYNX during pregnancy, they must contact their healthcare provider right away.
Common side effects in patients treated with NERLYNX
In clinical studies, the most common side effects seen in patients taking NERLYNX were diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis (dry or inflamed mouth, or mouth sores), decreased appetite, muscle spasms, dyspepsia, changes in liver blood test results, nail problems, dry skin, abdominal distention, weight loss and urinary tract infection.
Patients should tell their doctor right away if they are experiencing any side effects. Report side effects to the FDA at 1-800-FDA-1088 orhttp://www.FDA.gov/medwatch. Patients and caregivers may also report side effects to Puma Biotechnology at 1-844-NERLYNX (1-844-637-5969).
Please see Full Prescribing Information, available at http://www.NERLYNX.com.
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidates PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357. NERLYNX (neratinib) is approved for commercial use by prescription in the United States as extended adjuvant therapy for early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy and is marketed as NERLYNX. Neratinib is a potent irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4. Currently, the Company is primarily focused on the commercialization of NERLYNX and the continued development of its other advanced drug candidates directed at the treatment of HER2-positive breast cancer. The Company believes that NERLYNX has clinical application in the potential treatment of several other cancers that over-express or have a mutation in HER2.
Further information about Puma Biotechnology can be found at http://www.pumabiotechnology.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the benefits of NERLYNX and neratinib, the Companys clinical trials and the announcement of data relative to those trials. All forward-looking statements included in this press release involve risks and uncertainties that could cause the Companys actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, the fact that the Company has only recently commenced commercialization and shipment of its only FDA approved product; the Companys dependence upon the commercial success of NERLYNX (neratinib); the Companys history of operating losses and its expectation that it will continue to incur losses for the foreseeable future; risks and uncertainties related to the Companys ability to achieve or sustain profitability; the Companys ability to predict its future prospects and forecast its financial performance and growth; failure to obtain sufficient capital to fund the Companys operations; the effectiveness of sales and marketing efforts; the Companys ability to obtain FDA approval or other regulatory approvals in the United States or elsewhere for other indications for neratinib or other product candidates; the challenges associated with conducting and enrolling clinical trials; the risk that the results of clinical trials may not support the Companys drug candidate claims; even if approved, the risk that physicians and patients may not accept or use the Companys products; the Companys reliance on third parties to conduct its clinical trials and to formulate and manufacture its drug candidates; risks pertaining to securities class action, derivative and defamation lawsuits; the Companys dependence on licensed intellectual property; and the other risk factors disclosed in the periodic and current reports filed by the Company with the Securities and Exchange Commission from time to time, including the Companys Quarterly Report on Form 10-Q for the quarter ended June 30, 2017. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update these forward-looking statements, except as required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170830006310/en/
More here:
Puma Biotechnology Announces Publication of Abstracts for ESMO 2017 - Markets Insider
- Plant biotechnology 3 - Video - January 1st, 2014 [January 1st, 2014]
- Press Release - April 9th, 2014 [April 9th, 2014]
- Biotech Suffers Record Exit at Largest ETF Signaling Turn - April 9th, 2014 [April 9th, 2014]
- Biotechnology World Congress 2014 | Biotechnology ... - April 9th, 2014 [April 9th, 2014]
- What is Biotechnology? - Access Excellence @ the National ... - April 9th, 2014 [April 9th, 2014]
- What is Biotechnology? - BIO | Healing, Fueling and ... - April 9th, 2014 [April 9th, 2014]
- Biotechnology - Wikipedia, the free encyclopedia - April 9th, 2014 [April 9th, 2014]
- IUBP Day5 2 Emerging Opportunities in Biotechnology - Video - April 9th, 2014 [April 9th, 2014]
- B.Tech(Biotechnology), BATCH 2008/09, SVPUAT MEERUT.............. FRIENDS FOREVER...... - Video - April 9th, 2014 [April 9th, 2014]
- Bharat Book Presents : Global Pharmaceutical & Biotechnology Outlook 2014 Mature Biotech - Video - April 9th, 2014 [April 9th, 2014]
- Bharat Book Presents : Global Pharmaceutical & Biotechnology Outlook 2014 Japan Pharma - Video - April 9th, 2014 [April 9th, 2014]
- Bharat Book Presents : Global Pharmaceutical & Biotechnology Outlook 2014 India Pharma - Video - April 9th, 2014 [April 9th, 2014]
- Bharat Book Presents : Global Pharmaceutical & Biotechnology Outlook 2014 Rising Stars - Video - April 10th, 2014 [April 10th, 2014]
- Nasdaq Rout Curbs 2000-Like Boom in Israeli Share Sales - April 15th, 2014 [April 15th, 2014]
- A Glimpse into Biotechnology - Video - April 15th, 2014 [April 15th, 2014]
- Biotechnology: gel electrophoresis, PCR - Video - April 15th, 2014 [April 15th, 2014]
- Plandai Biotechnology, Inc. Qualifies for Grant From South African Department of Trade - Video - April 16th, 2014 [April 16th, 2014]
- Biotechnology Program - University of California, Davis - April 17th, 2014 [April 17th, 2014]
- Biotechnology in Action (Arizona) - Video - April 17th, 2014 [April 17th, 2014]
- France protests new EU approved genetically modified corn ScienceDaily - Video - April 17th, 2014 [April 17th, 2014]
- Drug manufacture and Biotechnology '14 - SCOPS - final phase ( Auditing ) - Video - April 19th, 2014 [April 19th, 2014]
- Mucosis Partners With Chinese Firm Changchun BCHT Biotechnology - April 22nd, 2014 [April 22nd, 2014]
- Biotechnology-2014: Meeting the Needs of a Changing World - April 22nd, 2014 [April 22nd, 2014]
- New patenting guidelines are needed for biotechnology - April 22nd, 2014 [April 22nd, 2014]
- Biotechnology is so cool - Video - April 22nd, 2014 [April 22nd, 2014]
- Bharat Book Presents : Biotechnology Equipment Markets in China - Video - April 22nd, 2014 [April 22nd, 2014]
- New patenting guidelines needed for biotechnology, experts argue - April 24th, 2014 [April 24th, 2014]
- biotechnology videos - Video - April 24th, 2014 [April 24th, 2014]
- Kristi Snell, VP Research and Biotechnology for Metabolix, Inc. - Video - April 24th, 2014 [April 24th, 2014]
- 4th Annual International Conference: Advances in Biotechnology 2014 - Video - April 24th, 2014 [April 24th, 2014]
- Edmonds School District Biotechnology - Video - April 25th, 2014 [April 25th, 2014]
- World congress on Biotechnology - Video - April 25th, 2014 [April 25th, 2014]
- Bahir Dar university biotechnology dr tESFAYE - Video - April 25th, 2014 [April 25th, 2014]
- Algenist Skincare: Biotechnology from San Francisco - Video - April 27th, 2014 [April 27th, 2014]
- nitj biotechnology farewell batch2010-14 - Video - April 28th, 2014 [April 28th, 2014]
- Life Sciences & Biotechnology - Video - April 28th, 2014 [April 28th, 2014]
- Bolder Biotechnology Current Therapeutic Market Developmental Pipeline - Video - April 28th, 2014 [April 28th, 2014]
- Academic and Research Institutions to Play Key Role in 2014 BIO International Convention - April 29th, 2014 [April 29th, 2014]
- 19 Biotechnology - Video - April 29th, 2014 [April 29th, 2014]
- BIOTECHNOLOGY - Video - April 29th, 2014 [April 29th, 2014]
- Program Spotlight: Biotechnology - Video - April 30th, 2014 [April 30th, 2014]
- Biotechnology at Gaston College - Video - April 30th, 2014 [April 30th, 2014]
- Biotechnology - Gene Cloning - Video - April 30th, 2014 [April 30th, 2014]
- Amyris helps launch Brazilian Industrial Biotechnology Association (ABBI) - Video - May 2nd, 2014 [May 2nd, 2014]
- Julius Mugwagwa - Agro-biotechnology and Food Security - Video - May 2nd, 2014 [May 2nd, 2014]
- VIRUN's CEO, Philip Bromley, lecture - Cal Poly Pomona; Biotechnology - Video - May 2nd, 2014 [May 2nd, 2014]
- Biotechnology - gel electrophoresis - Video - May 2nd, 2014 [May 2nd, 2014]
- Plant Biotechnology Information Fair at Penn State 4/18/14 - Video - May 2nd, 2014 [May 2nd, 2014]
- Biotechnology ADHK - Video - May 2nd, 2014 [May 2nd, 2014]
- General Biology 2 - 38 Angiosperm Reproduction and Biotechnology - Flashcards - Video - May 2nd, 2014 [May 2nd, 2014]
- Impact of Biotechnology on Current Life - Video - May 3rd, 2014 [May 3rd, 2014]
- DGAP-Adhoc: Cytos Biotechnology Ltd to wind down Key Operational Activities - May 5th, 2014 [May 5th, 2014]
- Process - Genetic Engineering and Biotechnology - Video - May 6th, 2014 [May 6th, 2014]
- SAT105 Unit 3 Part 2 Biotechnology - Video - May 6th, 2014 [May 6th, 2014]
- highlights of industrial biotechnology - Video - May 6th, 2014 [May 6th, 2014]
- polymer & environmental biotechnology @ acib - Video - May 8th, 2014 [May 8th, 2014]
- SAT105 Unit 3 Part 1 Biotechnology - Video - May 8th, 2014 [May 8th, 2014]
- Talk of the Trade: Biotechnology & Health Sciences - Video - May 9th, 2014 [May 9th, 2014]
- Congratulations to the 2014 Biotechnology Graduates of Athens Technical College! - Video - May 9th, 2014 [May 9th, 2014]
- Plandai Biotechnology (PLPL) - Getting the Most Out of Nature - Video - May 10th, 2014 [May 10th, 2014]
- Stages Of Beans Growth- HU biotechnology - Video - May 11th, 2014 [May 11th, 2014]
- Revisiting the biotechnology stocks - Video - May 11th, 2014 [May 11th, 2014]
- Molecular Biotechnology - Master's Programme - Video - May 11th, 2014 [May 11th, 2014]
- Kevin Ahern's BB 350 (Biotechnology) 2014 - #22 - Video - May 12th, 2014 [May 12th, 2014]
- 5/5, Session 1 - Small biotechnology/Venture capital - Video - May 12th, 2014 [May 12th, 2014]
- Executive Interview - International Biotechnology Trust - Video - May 12th, 2014 [May 12th, 2014]
- Biotechnology Salaries | Salary.com - May 14th, 2014 [May 14th, 2014]
- Biotechnology | University of Wrocaw - Video - May 14th, 2014 [May 14th, 2014]
- JVS Bridges to College - Biotechnology Pathway Program - Video - May 16th, 2014 [May 16th, 2014]
- Biotechnology Paperslide Review by Khalizarek+Brian - Video - May 16th, 2014 [May 16th, 2014]
- Perceptions on the Future of Biotechnology by Robert Paarlberg (USA) - Video - May 16th, 2014 [May 16th, 2014]
- Plant Biotechnology - Video - May 16th, 2014 [May 16th, 2014]
- Playing with Biotechnology at the Age of 20: Kinshuk Mitra at TEDxOhioStateUniversity - Video - May 16th, 2014 [May 16th, 2014]
- biotechnology movie - Video - May 19th, 2014 [May 19th, 2014]
- New report details biotechnology's use in crops - May 20th, 2014 [May 20th, 2014]
- Biotechnology Stock Wins - Video - May 20th, 2014 [May 20th, 2014]
- Plant product of biotechnology - Video - May 21st, 2014 [May 21st, 2014]
- How Biotechnology Cure Diabetes - Video - May 22nd, 2014 [May 22nd, 2014]
- Exploring Laser-Material Interaction for Engineering, Biotechnology, and Medicine #DigInfo - Video - May 22nd, 2014 [May 22nd, 2014]
- Computers, Biotechnology, and Mass Communication - Video - May 22nd, 2014 [May 22nd, 2014]